Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer
Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care
調査の概要
詳細な説明
PRIMARY OBJECTIVES:
I. Test the feasibility of the study protocol in advanced cancer patients and co-parents (recruitment/retention, dosage and fidelity of the intervention; program acceptability of program; and logistics).
II. Evaluate the short-term impact of the program on the diagnosed parents', co-parents' and children's adjustment and family functioning using a within group design (pre- and posttest design).
III. Compare outcomes from the Enhancing Connections Palliative Program with similar outcomes obtained from the completed phase III trial (between group design) for the patients and children outcomes.
IV. Evaluate the longer term impact of the program on the co-parents' and children's adjustment, including bereavement outcomes when appropriate, using a within and across group design (pre- and posttest design).
OUTLINE:
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
After completion of the study, participants are followed-up at 6 months.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
PATIENTS
- Ages 25-65 years
- Have a diagnosis of incurable cancer of any type; at any time in the diagnosis as long as they have at least a 4 month life expectancy based on the opinion of the attending physician
- Read and write English among their languages of choice
- Parent must live at least 50% of the time in the home and have a child 5-17 years old living at home who has been told their parent's cancer diagnosis
CO-PARENTS
- Co-parents must reside with the consenting eligible cancer participant (and child) at least 50% of the time and be actively participating in the care of the child
- If a biological parent lives in the home, and is physically well themselves, this person must be the co-parent
- If a biological parent does not live in the home (or has died), the co-parent does not have to be a biological parent; therefore, co-parents may be step-parents, lesbian, gay, bi-sexual or transgender (LGBT) partners, grandparents, aunts, uncles, etc if they otherwise meet eligibility criteria
- He or she can read and write English among their languages of choice and agrees to attend the patient intervention sessions in person or by telephone
CHILDREN
- The patient and co-parent must agree to focus on the same child throughout the study and consent to have the child participate before the child's assent will be sought
- Children aged 5-13 years of age will participate with a waiver of assent
- Children aged 14-17 will assent to participate in the research study by signing a separate assent form
- Children of formal assenting age will be eligible to participate if they can read and write English among their languages of choice
ALL PARTICIPANTS
- Participants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the intervention
- Parents and co-parents selecting the telephone version of the intervention may live any distance from the University of Washington
Exclusion Criteria:
- Patients will be excluded if they are enrolled in hospice at time of enrollment; however, they will be allowed to continue in the study if they enroll in hospice after beginning the study
- The triad will be ineligible if any member lives in the home less than 50% of the time
- If any member of the triad retracts consent or assent prior to completion of the post-intervention surveys, then all members will be excluded from the study thereafter
- The child will be excluded if he or she has learning challenges as assessed by the patient or co-parent; patients and co-parents will be instructed to consider any formal diagnoses of a learning disability of the presence of an Individual Education Plan (IEP) when making this assessment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Supportive Care (Enhancing Connections program)
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone.
Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
|
補助研究
Complete Enhancing Connections program
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility of the Enhancing Connections program in advanced cancer patients and co-parents
時間枠:Up to 2 years
|
Recruitment and retention of all triads will be monitored.
Dosage and fidelity will be monitored for each intervention session.
Program acceptability (per session, overall, duration of program, interval between intervention sessions) will be assessed from a debriefing interview.
For logistics four areas will be monitored: rate of receipt of mailed materials both to participants and from participants; duration and type (whether telephone or in-person) of intervention sessions; rate of success in scheduling and completing intervention sessions with patient and co-parent; and quality of data on baseline, post-intervention and follow-up measures.
|
Up to 2 years
|
|
Change in adjustment and family functioning
時間枠:Baseline to 6 months
|
Descriptive statistics (e.g.
means, medians) will be used to describe the Enhancing Connections palliative care population.
Parents', co-parents and children's baseline scores [parent-reported] on standardized questionnaires will be compared with post-intervention and 6 month follow-up scores on the same measures.
|
Baseline to 6 months
|
|
Outcomes from the Enhancing Connections Palliative Program as measured by the Child Behavior Check List
時間枠:Up to 2 years
|
Linear mixed modeling based on Maximum Likelihood Estimation will be used to test the differences between the Child Behavior Check List results for the Enhancing Connections Palliative Program and the completed phase III trial (EC-R01).
|
Up to 2 years
|
|
Change in adjustment as measured by post-traumatic growth scores
時間枠:Baseline to 6 months
|
Enhancing Connection Palliative Program parents', co-parents' and children's post-traumatic growth scores will be compared with follow-up (6 month) scores on the same measure.
|
Baseline to 6 months
|
協力者と研究者
捜査官
- 主任研究者:Elizabeth Loggers、Fred Hutch/University of Washington Cancer Consortium
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 9667 (その他の識別子:Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (米国 NIH グラント/契約)
- NCI-2016-01640 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- RG9218011 (その他の識別子:Fred Hutch/University of Washington Cancer Consortium)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
進行性悪性新生物の臨床試験
-
Advanced Bionics完了重度から重度の難聴 | Advanced Bionics HiResolution™ Bionic Ear System の成人ユーザーの割合アメリカ
-
QIAGEN Gaithersburg, Inc完了呼吸器合胞体ウイルス感染症 | インフルエンザA | ライノウイルス | インフルエンザB | QIAGEN ResPlex II Advanced Panel | ヒトパラインフルエンザウイルスによる感染症 1 | パラインフルエンザ2型 | パラインフルエンザ3型 | パラインフルエンザ4型 | ヒトメタニューモウイルス A/B | コクサッキーウイルス/エコーウイルス | アデノウイルス B型/C型/E型 | コロナウイルスサブタイプ 229E | コロナウイルス亜型NL63 | コロナウイルスサブタイプOC43 | コロナウイルスサブタイプ HKU1 | ヒトボカウイルス | Artus インフルエンザ A/B RT-PCR 検査アメリカ
-
Extremity Medical募集変形性関節症 | 炎症性関節炎 | 手根管症候群 (CTS) | 外傷性関節炎後 | スカホルネート高度崩壊 (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | 舟状骨、台形、および台形高度崩壊 (STTAC) | 成人のキーンボック病 | ラジアルマルニオン | 尺骨転座 | 舟状骨癒合不全高度崩壊 (SNAC)アメリカ
アンケート管理の臨床試験
-
Fondazione Poliambulanza Istituto Ospedalieroわからない
-
Fondation Santé des Étudiants de Franceまだ募集していません思春期の行動 | メンタルヘルスの問題
-
Assistance Publique - Hôpitaux de Paris完了
-
Centre Georges Francois Leclerc積極的、募集していないステージ IV の非小細胞気管支肺癌であり、現在のフランスの推奨に従って第一選択治療の恩恵を受けるフランス
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridgeわからない筋骨格疾患 | 筋骨格系損傷
-
Centre Hospitalier Universitaire de Nīmes完了
-
Assistance Publique - Hôpitaux de Parisまだ募集していません